New Technology Biography
Evaluating new technologies in the regulated pharma environment can be slow and costly to both innovators and the end users doing the beta or evaluation testing. To reduce these challenges, the new technology and product evaluation program (NTAP) spearheaded by BioPlan Associates is designed to help kick-start innovation in bio/pharma manufacturing segments. The program helps ensure that the best technologies areevaluated, even when innovators are small or resource constrained.
The program streamlines the evaluation process and cuts down on internal staff time, both at new technologyinnovators and at the bioprocessing facilities evaluating suppliers’ new products. The program compresses external beta testing and postlaunch evaluations and takes the time-consuming responsibility for recruitingfacilities and the costly process for managing the evaluation process out of the hands of technology innovators. By leveraging our network of evaluators and field testing staff and providing access to global commercial process development facilities, we free up innovators’ staff from project and site management. This helps assure independent, cross-lab analysis and provides facility data comparability. It also cuts time tomarket and reduces site recruiting costs significantly.
The program benefits suppliers by providing high-value evaluations, getting new products into the right hands, and coordinating multisite testing with integrated, compiled data. The program benefits evaluators by giving them access to the most promising and cutting-edge technologies while eliminating the need to deal with multiple contacts from multiple suppliers. Rather than testing all technologies, BioPlan can provide available data from other commercial evaluations.Innovation is the lifeblood of the biopharma industry, fueling new efficiencies, greater quality, and cost reductions in manufacturing processes. New ways of introducing new technologies are needed to allow facilities to focus on core aspects of R&D and to provide better evaluation methods that significantly cut down on time to market and streamline the testing process. There is a strong desire in the industry, as our study observes, for innovation and an accompanying sense that cost reductions and improved quality will come about for production of current biologics, biosimilars, and for production in emerging markets using flexible processes. Suppliers and technology innovators have repeatedly demonstrated their commitment to investment in innovation and new technologies, and industry demand will continue to support and fund suppliers’ process improvements
Evaluating new technologies in the regulated pharma environment can be slow and costly to both innovators and the end users doing the beta or evaluation testing. To reduce these challenges, the new technology and product evaluation program (NTAP) spearheaded by BioPlan Associates is designed to help kick-start innovation in bio/pharma manufacturing segments. The program helps ensure that the best technologies areevaluated, even when innovators are small or resource constrained.
The program streamlines the evaluation process and cuts down on internal staff time, both at new technologyinnovators and at the bioprocessing facilities evaluating suppliers’ new products. The program compresses external beta testing and postlaunch evaluations and takes the time-consuming responsibility for recruitingfacilities and the costly process for managing the evaluation process out of the hands of technology innovators. By leveraging our network of evaluators and field testing staff and providing access to global commercial process development facilities, we free up innovators’ staff from project and site management. This helps assure independent, cross-lab analysis and provides facility data comparability. It also cuts time tomarket and reduces site recruiting costs significantly.
The program benefits suppliers by providing high-value evaluations, getting new products into the right hands, and coordinating multisite testing with integrated, compiled data. The program benefits evaluators by giving them access to the most promising and cutting-edge technologies while eliminating the need to deal with multiple contacts from multiple suppliers. Rather than testing all technologies, BioPlan can provide available data from other commercial evaluations.Innovation is the lifeblood of the biopharma industry, fueling new efficiencies, greater quality, and cost reductions in manufacturing processes. New ways of introducing new technologies are needed to allow facilities to focus on core aspects of R&D and to provide better evaluation methods that significantly cut down on time to market and streamline the testing process. There is a strong desire in the industry, as our study observes, for innovation and an accompanying sense that cost reductions and improved quality will come about for production of current biologics, biosimilars, and for production in emerging markets using flexible processes. Suppliers and technology innovators have repeatedly demonstrated their commitment to investment in innovation and new technologies, and industry demand will continue to support and fund suppliers’ process improvements
NewTechnology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
New Technology
EmoticonEmoticon